Elshad Hasanov
Overview
Explore the profile of Elshad Hasanov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akula V, Chen L, Acikgoz Y, Klein K, Yavuz B, Cevik L, et al.
NPJ Precis Oncol
. 2025 Mar;
9(1):60.
PMID: 40050446
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high....
2.
Moussa M, Khandelwal J, Wilson N, Malikayil K, Surasi D, Bathala T, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39939142
Background: Nivolumab plus ipilimumab (nivo/ipi) is a standard of care first-line (1 L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC), but its role in patients with metastatic,...
3.
Dason S, Goradia R, Heh V, Sood A, Lee M, Son Y, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102258.
PMID: 39615117
Introduction: Management of metastatic renal cell carcinoma (mRCC) is highly individualized and often involves cytoreductive nephrectomy (CN) and systemic therapy (ST). The optimal sequencing of CN and ST is uncertain....
4.
LaPelusa M, Chamseddine S, Tran Cao H, Xiao L, Hasanov E, Bhosale P, et al.
Oncology
. 2024 Oct;
:1-8.
PMID: 39427654
Introduction: Perioperative immunotherapy has shown promise in some patients with early-stage hepatocellular carcinoma (HCC). This study examined tissue and imaging biomarkers associated with pathologic response in a phase II clinical...
5.
Goodstein T, Goldberg I, Acikgoz Y, Hasanov E, Srinivasan R, Singer E
Curr Opin Oncol
. 2024 Apr;
36(3):186-194.
PMID: 38573208
Purpose Of Review: This review focuses on special populations poorly represented in current evidence-based practice for metastatic renal cell carcinoma (mRCC). This includes the elderly and frail, patients on immunosuppression...
6.
Wilson N, Acikgoz Y, Hasanov E
Int J Cancer
. 2023 Oct;
154(6):947-961.
PMID: 37823185
Non-clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. Compared to clear-cell RCC (ccRCC),...
7.
Liu X, Zhang Y, McGrail D, Zhang X, Lam T, Hoang A, et al.
Clin Cancer Res
. 2023 Aug;
29(19):4002-4015.
PMID: 37527013
Purpose: Immune checkpoint blockade (ICB) demonstrates durable clinical benefits in a minority of patients with renal cell carcinoma (RCC). We aimed to identify the molecular features that determine the response...
8.
Hasanov E, Jonasch E
Hematol Oncol Clin North Am
. 2023 Jun;
37(5):1005-1014.
PMID: 37270383
The development of brain metastases is a poor prognostic indicator in renal cell carcinoma. Regular imaging and clinical examinations are necessary to monitor the brain before or during systemic therapy....
9.
Alhalabi O, Thouvenin J, Negrier S, Vano Y, Campedel L, Hasanov E, et al.
Oncologist
. 2023 Jan;
28(5):433-439.
PMID: 36640141
Background: There remains a paucity of data regarding the efficacy of immune checkpoint therapy (ICT) combinations ± vascular endothelial growth factor (VEGF) targeted therapy (TT) in translocation renal cell carcinoma...
10.
Kaseb A, Guan Y, Yavuz B, Abbas A, Lu S, Hasanov E, et al.
J Hepatocell Carcinoma
. 2022 Oct;
9:1065-1079.
PMID: 36254201
Purpose: Child-Turcotte-Pugh class A (CTP-A) in unresectable hepatocellular carcinoma (HCC) is the standard criterion for active therapy and clinical trial enrollment. We hypothesized that insulin-like growth factor-1 (IGF-1) derived scores...